Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Keytruda Top Selling Drug for 3 Months on End: Encise October Data
November 9, 2020
- 1st Half Sales of 7 Major Japan Drug Makers Skid 1.9% on Price Cuts, COVID-19; Core Products Brisk
November 6, 2020
- Before Aducanumab AdCom, Eisai CEO Voices Hopes for Potential 1st Alzheimer’s Drug in 17 Years
November 6, 2020
- Eisai Racks Up 5.9% Sales Increase in April-September on Lenvima Growth, Despite Price Cuts, COVID-19
November 6, 2020
- In a Digital Push, Takeda Encouraging Sales Reps to Gain IT Qualification: Japan Chief
November 5, 2020
- Mitsubishi Tanabe Incurs 60 Billion-Plus Yen Operating Loss in 1st Half as Parkinson’s Program Lags
November 5, 2020
- Prescriptions Down at 41% of Medical Institutions due to COVID-19: Survey
November 5, 2020
- AstraZeneca Approached Us for Manufacturing of Coronavirus Vaccine Solution: JCR Exec
November 5, 2020
- Sosei, Aditum Bio Form New Firm to Develop Neurological Disease Drugs
November 4, 2020
- Astellas Now Aims at Peak Sales of 300-400 Billion Yen for Padcev with New Indications
November 4, 2020
- Shionogi/Tetra’s Cognitive Disorder Med Delivers Positive PII Data
November 4, 2020
- JCR Can Strike Global Licensing Deal for Lysosomal Therapies at Least by March-End: Chief
November 4, 2020
- Kyowa Kirin’s Overseas Sales Ratio Nears 50%, Driven by Crysvita in Europe, US: January-September
November 4, 2020
- Daiichi Sankyo Promoting Home Use of Inavir to Reduce COVID-19 Risk at Medical Institutions
November 4, 2020
- Shionogi Drops March-End Goal to Start Clinical Trials for COVID-19 Treatment
November 2, 2020
- Shionogi Sales Sag 9.3% in April-September on COVID-19, Price Cuts
November 2, 2020
- Daiichi Sankyo’s 6-Month Operating Profit Falls 32% on Higher SGA Costs for Enhertu, ADC R&D Spending
November 2, 2020
- Astellas Earnings Flounder in April-September on LOEs, Deal Terminations
November 2, 2020
- European Regulators Accept Aducanumab for Review: Biogen/Eisai
November 2, 2020
- Ex-Merck Serono President Leo Lee Becomes Japan Chief of Novartis
November 2, 2020
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…